Evaluation of Clinical Treatment of Multiple Myeloma Based on Multi-omics
Evaluation of Clinical Treatment of Multiple Myeloma Based on Multi-omics
With the emergence of new drugs, the short-term survival rate of multiple myeloma has been
 significantly increased. How ever, in clinical treatment, doctors found that different
 patients may present different clinical efficacy and adverse reactions when using standard
 treatment. Some studies have shown that gene and metabolic differences in patients with
 multiple myeloma may be an important factor affecting clinical efficacy.

 In this project, peripheral blood samples from patients with multiple myeloma will be studied
 by using the methods of genomics, metabonomics and analytical omic. It is expected to find
 biomarkers and genes related to clinical efficacy, adverse reactions, and blood concentration
 of bortezomib in peripheral blood samples. If the sample size is large enough, the project
 team expects to establish a prediction model for the efficacy and safety of bortezomib
 containing regimen for multiple myeloma patients through the above studies. Investigators
 hope that the evaluation system can provide a reference for clinical formulation of
 appropriate drug delivery scheme.
Inclusion Criteria:

 -  exposure group:

 1. Patients diagnosed with multiple myeloma.

 2. Patients with fluorescence in situ hybridization report results, and try to
 obtain genetic diagnosis results.

 -  healthy control group: Patients diagnosed without multiple myeloma, such as other
 chronic diseases or blood tumors.

 Exclusion Criteria:

 1. Patients without complete clinical information.

 2. Patients with malignant epidemic diseases.

 3. Patients with alcohol abuse or special dietary habit .

 4. Patients with digestive system diseases, such as inflammatory bowel disease,
 intestinal infectious disease or other diseases that may affect digestive system
 function.

 5. Patients with a history of gastrointestinal operation.

 6. Patients with severe renal insufficiency without regular dialysis.

 7. Patients with other possibilities who has severe liver or kidney function injury
 without intervention.